Log in

OTCMKTS:ELTPElite Pharmaceuticals Stock Price, Forecast & News

0.00 (-2.90 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $0.07
50-Day Range
MA: $0.08
52-Week Range
Now: $0.07
Volume287,297 shs
Average Volume772,263 shs
Market Capitalization$56.75 million
P/E RatioN/A
Dividend YieldN/A
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products segments. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 15mg and 30mg capsules, and 37.5mg tablets for the treatment of bariatrics under Adipex-P brand name; Lodrane D immediate release capsules for OTC allergy treatment; Methadone HCl 10mg tablets for pains under the Dolophine name; and Hydromorphone HCl 8mg tablets for pains under the Dilaudid name. The company also provides Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril name; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia name; Isradipine 2.5mg and 5mg capsules for cardiovascular diseases; Hydroxyzine HCl 10mg, 25mg, and 50mg tablets for antihistamine treatment under Atarax and Vistaril brand names; Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone name; and Trimipramine Maleate Immediate Release 25mg, 50mg, and 100mg antidepressant capsules under the Surmontil brand, as well as SequestOX, an immediate release Oxycodone with Naltrexone. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. It has a manufacturing and license agreement with Epic Pharma LLC; manufacturing and supply agreement with The PharmaNetwork LLC; development and license agreement with SunGen Pharma, LLC; and strategic marketing alliance with Glenmark Pharmaceuticals, Inc. USA. The company was founded in 1984 and is headquartered in Northvale, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:ELTP



Sales & Book Value

Annual Sales$18 million


Net Income$-2,240,000.00


Market Cap$56.75 million
Next Earnings Date8/14/2020 (Estimated)
OptionableNot Optionable
0.00 (-2.90 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ELTP News and Ratings via Email

Sign-up to receive the latest news and ratings for ELTP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Elite Pharmaceuticals (OTCMKTS:ELTP) Frequently Asked Questions

How has Elite Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Elite Pharmaceuticals' stock was trading at $0.0738 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ELTP stock has decreased by 9.2% and is now trading at $0.0670.
View which stocks have been most impacted by Coronavirus

When is Elite Pharmaceuticals' next earnings date?

Elite Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020.
View our earnings forecast for Elite Pharmaceuticals

How were Elite Pharmaceuticals' earnings last quarter?

Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP) posted its quarterly earnings data on Thursday, June, 14th. The specialty pharmaceutical company reported $0.00 earnings per share for the quarter. The specialty pharmaceutical company had revenue of $1.60 million for the quarter.
View Elite Pharmaceuticals' earnings history

Has Elite Pharmaceuticals been receiving favorable news coverage?

Press coverage about ELTP stock has trended very positive this week, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Elite Pharmaceuticals earned a news impact score of 4.0 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Elite Pharmaceuticals

Who are some of Elite Pharmaceuticals' key competitors?

What other stocks do shareholders of Elite Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Elite Pharmaceuticals investors own include Research Frontiers (REFR), Ibio (IBIO), Pharmacyte Biotech (PMCB), Ascent Solar Technologies (ASTI), Co-Diagnostics (CODX), Novavax (NVAX), Selecta Biosciences (SELB), SANUWAVE Health (SNWV), Sierra Oncology (SRRA) and Tonix Pharmaceuticals (TNXP).

Who are Elite Pharmaceuticals' key executives?

Elite Pharmaceuticals' management team includes the following people:
  • Mr. Nasrat Hakim, Chairman, CEO & Pres (Age 58)
  • Mr. Carter J. Ward, CFO, Chief Accounting Officer, Treasurer & Sec. (Age 55)
  • Mr. Douglas Plassche, Exec. VP of Operations (Age 55)
  • Dr. George Kenneth Smith J.D., M.B.A., Ph.D., VP of Legal
  • Ms. Dianne Will, VP of Investor Relations & Corp. Affairs

What is Elite Pharmaceuticals' stock symbol?

Elite Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ELTP."

How do I buy shares of Elite Pharmaceuticals?

Shares of ELTP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Elite Pharmaceuticals' stock price today?

One share of ELTP stock can currently be purchased for approximately $0.07.

How big of a company is Elite Pharmaceuticals?

Elite Pharmaceuticals has a market capitalization of $56.75 million and generates $18 million in revenue each year. Elite Pharmaceuticals employs 43 workers across the globe.

What is Elite Pharmaceuticals' official website?

The official website for Elite Pharmaceuticals is www.elitepharma.com.

How can I contact Elite Pharmaceuticals?

Elite Pharmaceuticals' mailing address is 165 LUDLOW AVENUE, NORTHVALE NJ, 07647. The specialty pharmaceutical company can be reached via phone at 201-750-2646 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.